A self-petition green card for Swiss professionals whose record already speaks for itself — no US employer, no PERM labor certification. UBS wealth managers, Roche and Novartis scientists, and ETH Zurich or EPFL researchers regularly hold the kind of documented record — high compensation, patents, publications, institutional prestige — that satisfies USCIS's extraordinary ability standard.
A green card built on Swiss professional and academic credentials.
Switzerland concentrates an unusual density of globally significant institutions in a small country. Zurich is one of the world's premier wealth management centers, and UBS — now Switzerland's dominant global bank following its 2023 acquisition of Credit Suisse — anchors a private banking and asset management sector that employs Swiss nationals in roles with documented compensation and client-advisory records well above typical benchmarks. Basel, less than an hour from Zurich, is the headquarters of Roche and Novartis, two of the largest pharmaceutical companies in the world by R&D investment.
A third strand is academic and technical research: ETH Zurich and its sister institution EPFL in Lausanne are both consistently ranked among the top technical universities in the world. Because EB-1A requires no job offer and no labor certification, Swiss professionals in any of these sectors can self-petition directly on the strength of their own record, then file the same evidence for an O-1A nonimmigrant visa while the green card is pending.
UBS & Swiss wealth management
Switzerland's dominant global bank post-Credit Suisse acquisition, plus numerous Swiss private banks; wealth management professionals anchor to critical role, high salary, and original contributions from advisory frameworks adopted within the firm.
Roche & Novartis
Basel-headquartered global pharmaceutical majors; scientists qualify through original contributions (drug candidates advanced through clinical development, documented with patents), scholarly articles, and critical role at the principal scientist or director level.
ETH Zurich
Consistently ranked among the top universities in the world, particularly in engineering, physics, and computer science; faculty satisfy original contributions, scholarly articles, judging, and critical role through professorships.
EPFL
ETH Zurich's sister federal institute in Lausanne, similarly ranked among the world's top technical universities; researchers build EB-1A records through the same evidentiary anchors as ETH Zurich faculty.
E-2 treaty available (since 1850)
One of the oldest US bilateral treaties of commerce still in force; provides Swiss founders and investors a nonimmigrant alternative, but does not itself lead to permanent residence the way EB-1A does.
Broader Swiss life sciences cluster
Beyond Roche and Novartis, the Basel and Zurich life sciences ecosystem includes numerous biotech companies, generating a deep bench of scientists with patent portfolios relevant to EB-1A filings.
Eligibility criteria
The EB-1A criteria for Swiss professionals.
Three of ten criteria must be satisfied, followed by a final merits determination. For Swiss professionals, banking cases lean on high salary, critical role, and original contributions; pharma cases lean on contributions, articles, and judging; academic cases lean on articles, contributions, and judging.
01 — PRIZES
Awards & prizes
Swiss National Science Foundation prizes, Latsis Prize, pharmaceutical industry recognitions, and banking sector awards from Swiss financial press.
02 — MEMBERSHIP
Exclusive membership
Swiss Academy of Sciences membership; membership requiring outstanding achievement as judged by recognized experts; editorial board service on major peer-reviewed journals.
03 — PRESS
Published material about the person
Neue Zürcher Zeitung and Finews for Swiss finance coverage; Nature News and STAT News for pharma and biotech coverage; Swiss and international trade press for technology and research.
04 — JUDGING
Judging others' work
Swiss National Science Foundation grant review panels; peer review for Nature, Cell, or leading finance journals; editorial board service; conference program committee service.
05 — CONTRIBUTIONS
Original contributions of major significance
An advisory framework adopted within a Zurich bank; a drug candidate or formulation method advanced through clinical development at Roche or Novartis; a research method adopted across the field at ETH Zurich or EPFL.
06 — ARTICLES
Scholarly articles
Publications in Nature Medicine, The Lancet, or the Journal of Medicinal Chemistry for pharma scientists; field-leading journals for ETH Zurich and EPFL researchers.
07 — CRITICAL ROLE
Critical or essential role
Director or MD at UBS or a Swiss private bank; principal scientist or director at Roche or Novartis; professorship at ETH Zurich or EPFL.
08 — HIGH SALARY
High salary
Senior Zurich banking and pharma compensation, benchmarked against equivalent US occupational pay bands.
Swiss EB-1A profiles
What qualifying records look like here.
Representative profiles from Swiss EB-1A petitions. Identifying details have been generalized.
Executive Director, Wealth Management
Global bank — Zurich
Cross-border advisory for ultra-high-net-worth family offices
Manages CHF 900M+ in assets under advisory across 30+ family office relationships
Compensation in the 92nd percentile per Swiss private banking survey data
Profiled in Neue Zürcher Zeitung on family office advisory trends
Advisory framework adopted as a template across the regional team
Criteria satisfied: critical role, high salary, press (NZZ), contributions (advisory framework adoption, documented with internal records and expert letters).
Principal Scientist
Global pharmaceutical company — Basel
Small-molecule formulation strategies for oncology candidates
16 US and EU patents; 13 publications in Journal of Medicinal Chemistry
Lead formulation scientist on 2 candidates advanced to Phase II
Peer reviewer for the Journal of Medicinal Chemistry
Compensation at 90th percentile per pharmaceutical industry R&D survey data
Criteria satisfied: contributions, articles (Journal of Medicinal Chemistry), judging (peer review), high salary.
Associate Professor
ETH Zurich — Department of Computer Science
Novel optimization methods for distributed machine learning systems
20 publications; senior-author papers at NeurIPS, ICML, and ICLR
2,400+ citations; method adopted by 5+ independent research groups
Swiss National Science Foundation grant as principal investigator
ICML area chair; invited speaker at 3 international AI conferences
Criteria satisfied: articles, contributions (method adoption and citation record), judging (ICML area chair), critical role (ETH Zurich faculty position).
EB-1A and the oldest E-2 treaty
Why self-petition beats a treaty investment for most Swiss applicants.
Switzerland's E-2 treaty with the US is one of the oldest in force, but E-2 requires an active, substantial investment and ongoing direction of the enterprise, and it does not itself lead to a green card. For Swiss professionals in banking, pharma, and research whose personal record — compensation, patents, publications, or institutional prestige — already tells a strong individual story, EB-1A is often the more direct path to permanent residence, and it can be filed alongside an O-1A nonimmigrant petition using the same evidentiary record.
There is no country cap wait for most Swiss applicants under current visa bulletin movement, meaning EB-1A frequently moves faster to a green card than employer-sponsored categories requiring PERM.
Treaty status
Switzerland holds one of the oldest E-2 Treaty Investor agreements with the United States, dating to an 1850 treaty of friendship, commerce, and navigation. Swiss founders and investors can pursue E-2 as a capital-driven nonimmigrant alternative. EB-1A remains the more direct path to a green card for professionals with a documented individual achievement record.
FAQ
Switzerland EB-1A questions.
Yes. EB-1A is a self-petition category — no US employer, job offer, or PERM labor certification is required. Swiss nationals in banking, pharma, or research file the I-140 directly with USCIS based on their own extraordinary ability record.
Swiss wealth management professionals build EB-1A records around critical role (director or MD-level positions at UBS or a Swiss private bank), high salary (compensation benchmarked against equivalent US finance industry pay bands), and original contributions corroborated by expert letters.
Yes. Roche and Novartis, both headquartered in Basel, are two of the largest pharmaceutical companies in the world, and their senior scientists frequently satisfy multiple EB-1A criteria — original contributions, scholarly articles, judging through peer review, and critical role at the principal scientist or director level.
ETH Zurich and EPFL are both consistently ranked among the top technical universities in the world. Faculty and senior researchers typically satisfy original contributions, scholarly articles, judging, and critical role — often reaching four or five criteria before the final merits review.
Switzerland's E-2 treaty, one of the oldest in force with the US, gives Swiss founders and investors a capital-driven nonimmigrant option, but E-2 does not lead to a green card on its own. EB-1A is the more direct route to permanent residence for Swiss professionals whose record already demonstrates extraordinary ability.
